CCR2 and focal segmental glomerulosclerosis: Here we report that a CCR2 selective small molecule antagonist markedly reduced proteinuria and improved renal function in both of these widely used murine FSGS models, both as a single agent and when given in combination with RAAS and/or endothelin receptor antagonists.